Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of GSK3179106 in Healthy Volunteers
NCT02798991Phase 1Completed
- Sponsor
- GSK
- Start
- Jun 2016
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GSK3179106 in irritable bowel syndrome (IBS) (7 arms), sponsored by GSK. Primary endpoint: Number of subjects with adverse event. Started Jun 2016; status: completed.
02
Drugs
GSK3179106
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on NCT02798991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02798991.